Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Neuropathology : Official Journal of the Japanese Society of Neuropathology|July 3, 2014
Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy caseMasayuki Shintaku, Nao Toyooka, Takashi Koyama, et al.
Clinical Lung Cancer|January 7, 2019
A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Yasuhiro Koh, et al.
Clinical Lung Cancer|May 16, 2019
Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L)Hiroaki Akamatsu, Shunsuke Teraoka, Satoshi Morita, et al.
International Journal of Clinical Oncology|May 10, 2025
How to report and discuss subgroup analyses in clinical practice guidelines? Evaluation procedure of the clinical and statistical relevancyKiichiro Ninomiya, Satoru Miura, Yuko Oya, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumoniaDaichi Fujimoto, Takeshi Morimoto, Jiro Ito, et al.
Acute Medicine & Surgery|May 10, 2021
Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency departmentKatsuyuki Furuta, Hiroaki Akamatsu, Ryuichi Sada, et al.
Clinical Lung Cancer|June 24, 2018
Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical TrialsHayato Kawachi, Daichi Fujimoto, Takeshi Morimoto, et al.
Respiratory Care|December 8, 2016
Enteral Nutrition Is a Risk Factor for Airway Complications in Subjects Undergoing Noninvasive Ventilation for Acute Respiratory FailureMariko Kogo, Kazuma Nagata, Takeshi Morimoto, et al.
JTO Clinical and Research Reports|April 3, 2023
First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWNHidetoshi Hayashi, Shunsuke Teraoka, Yasushi Goto, et al.
JTO Clinical and Research Reports|March 4, 2024
Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC-A Brief Report From the CROWN StudyShunsuke Teraoka, Hidetoshi Hayashi, Yasushi Goto, et al.
Pageof 6